Analysis of national data by King’s College London researchers has found that patients who survive sepsis are at higher risk of death for up to five years.
Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one.